167 related articles for article (PubMed ID: 1385047)
1. Decay accelerating factor (CD55).
Nicholson-Weller A
Curr Top Microbiol Immunol; 1992; 178():7-30. PubMed ID: 1385047
[No Abstract] [Full Text] [Related]
2. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M
Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401
[No Abstract] [Full Text] [Related]
3. Evidence that double transfection to xenoendothelial cells using GPI-anchoring complement regulatory factor (decay-accelerating factor and homologous restriction factor 20) gene is useful for the inhibition of human complement-mediated cytolysis.
Hayashi S; Isobe K; Emi N; Okada H; Yasutomi M; Negita M; Koike C; Uchida K; Yokoyama I; Takagi H
Transplant Proc; 1995 Feb; 27(1):330. PubMed ID: 7533402
[No Abstract] [Full Text] [Related]
4. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor.
Oglesby TJ; White D; Tedja I; Liszewski K; Wright L; Van den Bogarde J; Atkinson JP
Trans Assoc Am Physicians; 1991; 104():164-72. PubMed ID: 1726964
[No Abstract] [Full Text] [Related]
5. A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.
Tambourgi DV; Kipnis TL; da Silva WD; Joiner KA; Sher A; Heath S; Hall BF; Ogden GB
Infect Immun; 1993 Sep; 61(9):3656-63. PubMed ID: 7689538
[TBL] [Abstract][Full Text] [Related]
6. Membrane inhibitor of reactive lysis.
Holguin MH; Parker CJ
Curr Top Microbiol Immunol; 1992; 178():61-85. PubMed ID: 1385046
[No Abstract] [Full Text] [Related]
7. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection.
Cary N; Moody J; Yannoutsos N; Wallwork J; White D
Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815
[No Abstract] [Full Text] [Related]
8. Relative roles of hCD46 and hCD55 in the regulation of hyperacute rejection.
Verbakel CA; Bonthuis F; Eerhart SE; van Dixhoorn M; Grosveld F; Marquet RL; IJzermans JN
Transplant Proc; 2000 Aug; 32(5):903-4. PubMed ID: 10936266
[No Abstract] [Full Text] [Related]
9. Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis.
Charreau B; Cassard A; Tesson L; Le Mauff B; Blanchard D; Lublin D; Soulillou JP; Anegon I
Transplant Proc; 1995 Feb; 27(1):336-7. PubMed ID: 7533404
[No Abstract] [Full Text] [Related]
10. Mice transgenic for human CD46 and CD55 are protected from human complement attack.
Mulder LC; Mora M; Ciccopiedi E; Melli C; Nuti S; Marinucci G; Bruzzone P; Lazzeri M; Lorenzini R; Alfani D
Transplant Proc; 1995 Feb; 27(1):333-5. PubMed ID: 7533403
[No Abstract] [Full Text] [Related]
11. [Complement regulatory proteins].
Miyagawa S
Nihon Rinsho; 2005 Apr; 63 Suppl 4():274-8. PubMed ID: 15861668
[No Abstract] [Full Text] [Related]
12. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.
Higgins PJ; Ko JL; Lobell R; Sardonini C; Alessi MK; Yeh CG
J Immunol; 1997 Mar; 158(6):2872-81. PubMed ID: 9058824
[TBL] [Abstract][Full Text] [Related]
13. Expression of human decay accelerating factor in transgenic pigs.
Cozzi E; Langford GA; Richards A; Elsome K; Lancaster R; Chen P; Yannoutsos N; White DJ
Transplant Proc; 1994 Jun; 26(3):1402-3. PubMed ID: 7518135
[No Abstract] [Full Text] [Related]
14. Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.
Parker CJ
Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):36-42. PubMed ID: 1718642
[No Abstract] [Full Text] [Related]
15. Adenovirus-mediated gene transfer of the triple human complement regulating proteins (DAF, CD59, MCP) in xenogeneic pig liver perfusion.
Shiraishi M; Nagahama M; Nozato E; Oshiro T; Taira K; Muto Y
Transplant Proc; 2000 Aug; 32(5):1116-7. PubMed ID: 10936387
[No Abstract] [Full Text] [Related]
16. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
17. Production of pigs transgenic for human decay accelerating factor.
Langford GA; Yannoutsos N; Cozzi E; Lancaster R; Elsome K; Chen P; Richards A; White DJ
Transplant Proc; 1994 Jun; 26(3):1400-1. PubMed ID: 7518134
[No Abstract] [Full Text] [Related]
18. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
19. Decay-accelerating factor and membrane cofactor protein.
Lublin DM; Atkinson JP
Curr Top Microbiol Immunol; 1990; 153():123-45. PubMed ID: 1688754
[No Abstract] [Full Text] [Related]
20. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
